RT Journal Article
T1 Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.
A1 Montes, Ariana
A1 Perez-Pampin, Eva
A1 Navarro-Sarabia, Federico
A1 Moreira, Virginia
A1 Rodríguezde la Serna, Arturo
A1 Magallares, Berta
A1 Vasilopoulos, Yiannis
A1 Sarafidou, Theologia
A1 Fernández-Nebro, Antonio
A1 Ordóñez, María Del Carmen
A1 Narváez, Javier
A1 Cañete, Juan D
A1 Marquez, Ana
A1 Pascual-Salcedo, Dora
A1 Joven, Beatriz
A1 Carreira, Patricia
A1 Moreno-Ramos, Manuel J
A1 Caliz, Rafael
A1 Ferrer, Miguel Angel
A1 Garcia-Portales, Rosa
A1 Blanco, Francisco J
A1 Magro, Cesar
A1 Raya, Enrique
A1 Valor, Lara
A1 Alegre-Sancho, Juan J
A1 Balsa, Alejandro
A1 Martin, Javier
A1 Plant, Darren
A1 Isaacs, John
A1 Morgan, Ann W
A1 Barton, Anne
A1 Wilson, Anthony G
A1 Gómez-Reino, Juan J
A1 Gonzalez, Antonio
K1 Artritis reumatoide
K1 Genotipo
K1 Articulaciones
K1 Enfermedades reumáticas
K1 Factor de necrosis tumoral alfa
AB INTRODUCTIONWe have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA).METHODSThe G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria.RESULTSAn association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication.CONCLUSIONSOur results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA.
PB BioMed Central
SN 1478-6354
YR 2015
FD 2015-03-18
LK http://hdl.handle.net/10668/2176
UL http://hdl.handle.net/10668/2176
LA en
NO Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, et al. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Res. Ther. 2015; 17:63
NO Journal Article;
DS RISalud
RD Apr 9, 2025